Troy Cox
Troy Cox's purchase track record
Troy Cox has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/28/2026 | MPLT | $149K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum. Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.
Transaction History
| MPLT | ▲ Buy | Open Market | 15,620 | $149K | 7/28/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 7,864 | $0 | 6/23/2026 | View on chart |
| LAB | ▲ Buy | Grant | 99,116 | $0 | 6/18/2026 | View on chart |
| SOPH | ▲ Buy | Grant | 19,724 | $108K | 6/18/2026 | View on chart |
| LAB | ▲ Buy | Grant | 57,264 | $67K | 2/26/2026 | View on chart |
| LAB | ▲ Buy | Grant | 94,592 | $0 | 6/20/2025 | View on chart |
| LAB | ▲ Buy | Grant | 62,910 | $67K | 2/28/2025 | View on chart |
| LAB | ▲ Buy | Grant | 43,128 | $0 | 6/28/2024 | View on chart |
| LAB | ▲ Buy | Grant | 87,057 | — | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 79,412 | $0 | 1/5/2024 | View on chart |
| LAB | ▲ Buy | Grant | 31,635 | — | 1/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.